AB 5006
Alternative Names: AB-5006; AX-5006Latest Information Update: 31 Mar 2023
At a glance
- Originator Axial Biotherapeutics
- Developer Axial Therapeutics
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Escherichia coli csgA protein aggregation inhibitors; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 29 Mar 2023 Axial Therapeutics plans to file an IND application for Parkinson's disease
- 29 Mar 2023 Axial Therapeutics plans a phase I trial for Parkinson's disease in 2024
- 19 Oct 2021 Preclinical trials in Parkinson's disease in USA (unspecified route) (Axial Biotherapeutics pipeline, October 2021)